%0 Journal Article
%T Alpha-Stim AID Cranial Electrotherapy Stimulation (CES) for Anxiety Treatment: Outcomes in a Community Healthcare Service
%A Chris Griffiths
%A Leno Joseph
%A Doreen Caesar
%A Bharath Lakkappa
%A Chloe Leathlean
%A Ksenija da Silva
%J Open Journal of Depression
%P 80-92
%@ 2169-9674
%D 2022
%I Scientific Research Publishing
%R 10.4236/ojd.2022.114007
%X <b><span style=\"font-family:Verdana;\">Background:</span></b><span style=\"font-family:Verdana;\"> Symptoms of anxiety disorders are highly common and can have a severe
impact on people¡¯s lives; they are typically treated with psychotherapy and/or
anti-anxiety medication. These treatments are not suitable for, acceptable to,
or effective for everyone. Alpha-Stim AID is a cranial electrotherapy
stimulation (CES) device with evidence of effectiveness in treating symptoms of
anxiety. In this study, Alpha-Stim AID was offered through a United Kingdom
(UK) universal community healthcare provider</span><span style=\"font-family:Verdana;\">,</span><span style=\"font-family:&quot;\"><span style=\"font-family:Verdana;\"> Intermediate Care Team (ICT) community healthcare
service to patients who reported signs of anxiety. </span><b><span style=\"font-family:Verdana;\">Objective:</span></b><span style=\"font-family:Verdana;\"> The aim of
this paper is to present feasibility findings and outcomes on anxiety, health
status, and quality of life. </span><b><span style=\"font-family:Verdana;\">Methods:</span></b><span style=\"font-family:Verdana;\"> Open-label patient cohort design,
with no control group. Participants were adults who reported symptoms of
anxiety and were under the care of universal national health service (NHS)
Intermediate Care Team (ICT) community healthcare service in the United Kingdom
(UK). Pre- and post-intervention assessment us</span></span><span style=\"font-family:Verdana;\">ed</span><span style=\"font-family:&quot;\"><span style=\"font-family:Verdana;\"> participant self-report measures: generalised
anxiety disorder (GAD-7) and health related quality of life (EQ-5D-5L). The
three ICT staff members who offered the Alpha-Stim AID to patients completed a
questionnaire on their experience. </span><b><span style=\"font-family:Verdana;\">Results:</span></b><span style=\"font-family:Verdana;\"> Eighteen patients used the
Alpha-Stim and completed outcome measures. GAD-7 scores significantly improved
from 13.9 (SD = 4.3) to 7.3 (SD = 5.7) (</span><i><span style=\"font-family:Verdana;\">p</span></i><span style=\"font-family:Verdana;\"> &lt; 0.001), with a large effect size of 0.88. Analysis of EQ-ED-5L health
index score conversions indicated perceived quality of life increased from 0.31
(SD = 0.25) to 0.48 (SD = 0.28) at end (</span><i><span style=\"font-family:Verdana;\">p</span></i><span style=\"font-family:Verdana;\"> = 0.036), with a small effect size of 0.12. EQ-VAS scores at baseline improved
from 49.2 (SD = 24.0) to 64.4 (SD = 26.2) at the end
%K Alpha-Stim
%K Community Care
%K Cranial Electrotherapy Stimulation
%K Service Delivery
%K Anxiety
%K Depression
%K Quality of Life
%K Co-Morbidity
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=121330